Maryland State Retirement & Pension System Has $912,000 Position in Hologic, Inc. (NASDAQ:HOLX)

Maryland State Retirement & Pension System lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 12,657 shares of the medical equipment provider’s stock after selling 542 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Hologic were worth $912,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of HOLX. General Partner Inc. bought a new position in Hologic in the 4th quarter valued at about $26,000. Groupama Asset Managment increased its stake in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC lifted its holdings in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares during the period. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the subject of a number of research reports. Jefferies Financial Group began coverage on Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price for the company. Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a research note on Monday, February 3rd. Royal Bank of Canada cut their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Finally, BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Price Performance

HOLX stock opened at $61.47 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67. The company has a market capitalization of $13.79 billion, a P/E ratio of 19.39, a PEG ratio of 2.14 and a beta of 0.97. The company has a fifty day moving average price of $66.06 and a 200-day moving average price of $73.94.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.